RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $80 from $75 and keeps an Outperform rating on the shares. The firm expects Edwards to discuss its product and clinical pipeline in detail at its 2024 Investor Conference on December 4, as well as provide a financial outlook for 2025 that is likely to be typically conservative ahead of the start of the year, likely encompassing consensus, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences announces presentation of one-year SAPIEN 3 data
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences Evoque demonstrated superiority vs. medical therapy alone
- Raymond James says Edwards’ EARLY TAVR data also positive for Medtronic, Abbott